Keith Gregory Heinzerling MD
Addiction Medicine
Director, Pacific TRIP Program at Pacific Neuroscience Institute
Join to View Full Profile
1301 20th StSte 540Santa Monica, CA 90404
Phone+1 310-582-7612
Fax+1 424-277-6342
Dr. Heinzerling is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
NYU Grossman School of MedicineResidency, Internal Medicine, 1998 - 2002
Stanford University School of MedicineClass of 1998
Certifications & Licensure
CO State Medical License 2025 - 2027
CA State Medical License 2002 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Preventive Medicine Addiction Medicine
American Board of Addiction MedicineAddiction Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Trial of Ibudilast for Methamphetamine Dependence Start of enrollment: 2013 Jul 01
- Study of Pomaglumetad and Methamphetamine Start of enrollment: 2017 Aug 01
- Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder Start of enrollment: 2021 Feb 18
Publications & Presentations
PubMed
- 169 citationsSingle-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.Charles L Raison, Gerard Sanacora, Joshua Woolley, Keith Heinzerling, Boadie W Dunlop
JAMA. 2023-09-05 - 5 citationsPsychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology.Daniel F Kelly, Keith Heinzerling, Akanksha Sharma, Shanthi Gowrinathan, Karina Sergi
Neurosurgery. 2023-04-01 - 6 citationsNature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder.Keith G Heinzerling, Karina Sergi, Micah Linton, Rhianna Rich, Brittany Youssef
Frontiers in Psychiatry. 2023-01-01
Press Mentions
Why Naltrexone Is Considered the ‘Ozempic for Alcohol’ Use DisorderOctober 18th, 2024- Mental Health Treatments: Australia OKs MDMA, Psilocybin, but What Does This Mean?February 10th, 2023
- Psychedelics in Medicine: Where We Are, Where We're GoingOctober 1st, 2021
- Join now to see all
Grant Support
- Pharmacogenomics And Medication Development For Methamphetamine DependenceNational Institute On Drug Abuse2008–2012
- Pilot Trial Of Bupropion Versus Placebo For Methamphetamine Abuse In AdolescentsNational Institute On Drug Abuse2009–2010
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
